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The taxanes are a novel family of anti-cancer drugs, which has
developed clinical significance in the past two decades; they are
used mainly in advanced or metastatic breast and non-small-cell
lung cancer (NSCLC) (Vaishampayan et al, 1999; Munster and
Judis, 2000). Unlike other tubuline-binding agents such as the
vinca alkaloids, which promote microtubule disassembly, the
taxanes stabilize microtubules by preventing depolymerization,
resulting in cell death. There are 2 structure-related members in
the taxane family: paclitaxel and docetaxel. 
Paclitaxel (taxol) was originally a natural product derived from
the bark of the North American yew tree, Taxus brevufola. The
chief adverse effects of paclitaxel are hypotension, arrthymia,
neutropenia, peripheral neuropathy, nausea with vomiting, pneu-
monitis, and hypersensitivity reaction (Tamura et al, 1995; Furuse
et al, 1997; Choy et al, 1998); the last may be attributed to both
paclitaxel and its diluent, and can be reduced by premedications
with steroid and histamine receptor antagonists. 
Docetaxel (taxotere) is a chemically semi-synthesized com-
pound derived from the extract of the needles of the European
yew, Taxus baccata, and entered clinical trials in the 1990s. The
chief adverse effects of docetaxel are neutropenia, hypersensitivity
reaction, peripheral neuropathy, typhlitis, peripheral oedema, and
very rarely, pneumonitis (Kunitah et al, 1996; Earhart, 1999;
Fossella, 1999; Ibrahim et al, 2000). 
Pneumonitis is an unusual side effect of the taxanes; there have
been few reports about it. Phase II trials of paclitaxel disclosed an
approximately 3% incidence rate of interstitial pneumonitis in
patients with previously untreated advanced NSCLC (Furuse et al,
1997), and a 12% rate in patients with locally advanced NSCLC
receiving concurrent radiotherapy (Choy et al, 1998). The precise
mechanism of pneumonitis is not well-known, but may be related
to hypersensitivity pneumonitis and precipitated by chest radiation
(Schweitzer et al, 1995; Khan et al, 1997; Fujimori et al, 1998),
since the taxanes, both paclitaxel and docetaxel, are potent
radiosensitizers. 
Only 6 cases, in which patients with advanced NSCLC treated
with docetaxel suffered from acute interstitial pneumonitis, are
mentioned in the literature (Kunitah et al, 1996; Merad et al, 1997;
Etienne et al, 1998); of these, 5 patients recovered with cortico-
steroid treatment and one died of respiratory failure. The incidence
rate was around 3%, as described in a small phase II series
(Kunitah et al, 1996). 
We report 4 cases of advanced NSCLC developing acute life-
threatening bilateral interstitial pneumonitis and respiratory failure
after 1–6 courses of docetaxel therapy, and discuss the phenom-
enon. 
CASE REPORTS 
Case 1 
A 44-year-old female was diagnosed in March 1999 with stage IV
adenocarcinoma of the lung, right lower lobe, with lung-to-lung
metastases, lymphangitic spreading, and multiple bone metastases.
She received local palliative radiotherapy with 3000 cGy to the
lumbar 4–5 spine and left sacroiliac joint, followed by 6 courses of
chemotherapy with cisplatin and etoposide, ending in August
1999. Failure of treatment led to her further receiving second-line
chemotherapy with weekly docetaxel. The first dose of docetaxel,
at 44 mg (33 mg m–2), was infused within one hour on 20
September 1999, with premedications of steroid and anti-emesis
agents. She developed severe shortness of breath and was sent to
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time revealed acute diffuse interstitial infiltrates, and marked
hypoxemia was observed. She was then intubated with mechanical
ventilatory support and immediately admitted to the intensive care
unit; the post-intubation arterial blood analysis revealed that the
arterial partial pressure of oxygen (PaO2) was 166.9 mmHg, at a
fraction of inspired oxygen (FiO2) 0.5. 
Empiric broad-spectrum intravenous antibiotics were used
initially because of her moderate-grade fever (38.5˚C) and blood
leukocytosis (WBC 130 00 cumm–1), without a significant bacte-
rial culture result. Her condition progressively became worse, and
the PaO2 was 72 mmHg at FiO2 0.5 by the 5th day of admission.
Intravenous hydrocortisone at 300 mg every 6 hours was then
prescribed for the suspicion of drug-induced pneumonitis. Blood
oxygenation mildly improved (PaO2 73.2 mmHg at FiO2 0.35) in
the following 10 days. However, when the dosage of corticosteroid
was tapered off, blood oxygenation deteriorated. Nosocomial
urosepsis and septic shock developed after 3 weeks of high-dose
corticosteroid therapy, and her condition worsened thereafter. She
died on October 29, 1999. 
Case 2 
A 73-year-old male was diagnosed with stage IV NSCLC, right
lower lobe, with bone metastases in May 1998. He received 6
courses of chemotherapy with vinorelbine (navelbine) and
cisplatin, later followed by 3 courses of tamoxifen, ifosfamide,
etoposide, and cisplatin (TIEP) because of progressive disease. In
July 1999, TIEP was withdrawn because of neurologic toxicities,
and he began to receive weekly docetaxel 53.7 mg (30 mg m–2),
and gemcitabine 1432 mg (800 mg m–2) every 3 weeks. A total of
6 courses were finished on 5 November 1999. The cumulative
dosage of docetaxel was 644.4 mg. Unfortunately, he developed
shortness of breath with exacerbated weakness, and visited the
emergency department 2 weeks after the last dose of docetaxel.
The chest X-ray and chest computed tomography (CT) revealed
acute diffuse thickening lobular septa with areas of ground glass
opacities, which suggested drug-induced lung injury. He was intu-
bated with mechanical ventilatory support for impending respira-
tory failure when the PaO2 had reached 138.7 mmHg at FiO2 1.0. 
He was admitted to the intensive care unit immediately and
treated with intravenous hydrocortisone at 300 mg every 6 hours,
but with little effect. A transbronchial lung biopsy (TBLB)
performed on the 5th day of admission revealed chronic inflamma-
tion and interstitial fibrosis. The serum cytomegalovirus (CMV)
antibody, legionella antibody/antigen, and anti-human immunode-
ficiency virus (HIV) antibody were all negative. Subsequently, he
developed secondary pulmonary infection, sepsis, and multiple-
organ failure syndrome. He died on the 9th day of admission. 
Case 3 
A 70-year-old male was diagnosed with stage IIIa squamous cell
lung cancer, left lower lobe, in May 1998. He refused surgical
intervention and received 3 courses of paclitaxel and cisplatin,
followed by 6 courses of gemcitabine and vinorelbine, ending in
January 1999. Relapse of the disease was noted in March 1999. He
accepted pulmonary radiotherapy with 5993 cGy, but the tumour
continue to enlarge, and radiation pneumonitis occurred 4 months
after finishing radiotherapy. Since the treatment had failed, he was
then treated with weekly docetaxel 51 mg (30 mg m–2), and gemc-
itabine 1360 mg (800 mg m–2) every 3 weeks. A total of 6 courses
were administered until 5 November 1999; the cumulative dosage
of docetaxel was 612 mg. He developed dyspnoea on exertion and
shortness of breath about 3 weeks after the last dose of
chemotherapy, and rapidly deteriorated to impending respiratory
failure on 29 November. He was intubated with mechanical venti-
lator support when the PaO2 was 121.3 mmHg at FiO2 1.0, and was
admitted to the intensive care unit. 
The chest CT revealed increased interstitial infiltrates compared
with the prior images (Figure 1). A TBLB performed 3 days after
admission revealed chronic inflammatory changes. Docetaxel-
induced pneumonitis was diagnosed. Intravenous methylpred-
nisolone at 60 mg every 6 hours had been prescribed since
admission. The blood oxygenation remained stationary in the
initial few days; PaO2 was 81 mmHg at FiO2 0.7. Unfortunately,
nosocomial pneumonia with septic shock occurred one week later,
and he died on the 12th day of admission. 
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Figure 1 Serial chest computed tomographs of case 3. (A) The chest
computed tomograph was taken on November 5, 1999, when the 6 courses
of chemotherapy with docetaxel and gemcitabine had just finished. This film
shows mild fibrotic changes in both lungs that were compatible with radiation
pneumonitis (6 months after finishing chest radiotherapy). (B). The chest
computed tomograph was taken on November 30, 1999, one day after his
last admission, when he developed severe hypoxemia and respiratory failure.
This film shows coarse reticular interstitial and nodular infiltrations in the right
lung field and left perihilar region that were compatible with hypersensitivity
pneumonitis. Because of the rapid progression of the interstitial process,
disseminated malignant disease or other systemic disease was excluded
first; in addition to exposure history, clinical course, and laboratory data,
including transbronchial lung biopsy, docetaxel-induced hypersensitivity
pneumonitis was diagnosed Case 4 
A 75-year-old male was diagnosed with adenocarcinoma, right
lower lobe, and underwent a right pneumonectomy in July 1999.
Since the post-operation staging was stage IIIb (N3), he received a
subsequent 6 courses of chemotherapy with gemcitabine and
cisplatin, ending in September 1999. Unfortunately, the disease
progressed thereafter. He then received second-line chemotherapy
with tri-weekly docetaxel 92.4 mg (60 mg m–2) on 10 October and
74 mg (48 mg m–2) on 31 October (the dosage was reduced to 80%
due to neutropenic fever developing after the first dose). He devel-
oped dyspnoea 2 weeks after the second dose of docetaxel and
rapidly progressed to severe hypoxaemia. He was intubated with
mechanical ventilatory support and admitted to the intensive care
unit on 30 November, when the PaO2 was 77.6 mmHg at FiO2 0.9. 
The chest X-ray revealed diffuse interstitial infiltrates.
Intravenous hydrocortisone at 300 mg every 6 hours had been
initiated since admission for the high suspicion of docetaxel-
induced pneumonitis. Blood oxygenation improved during the
initial 6 days, with a PaO2 66.7 mmHg at FiO2 0.4. Unfortunately,
left tension pneumothorax occurred on the 10th admission day,
and then a bronchopleural fistula developed. He died on the 16th
admission day. 
DISCUSSION 
Many cytotoxic drugs such as bleomycin, methotrexate, nilu-
tamide and procarbazine, antibiotics such as penicillin, ampicillin
and minocycline, cardiovascular drugs such as propanolol and
amiodarone, and other drugs such as chlorpropamide, isoniazid
and hydralazine, can induce hypersensitivity pneumonitis (Holoye
et al, 1978; Cooper et al, 1986a,b; Akoun et al, 1989, 1990;
Guillon et al, 1992). This usually occurs acutely, unrelated to the
cumulative dose of the drug or the duration of therapy, and
responds well to corticosteroid treatment. Occasionally, peripheral
eosinophilia has been noted, involving about 10 to 20% of the
white blood cells, and may signal a favourable prognosis with
complete resolution (Cooper et al, 1986). The pathology has found
patchy eosinophilic infiltrates affecting the distal air spaces, with a
relative sparing of the proximal airways and an absence of immune
deposits (Holoye et al, 1978). Bronchoalveolar lavage (BAL) in
these patients revealed lymphocytic alevolitis, a reverse lympho-
cyte subpopulation ratio, and increased eosinophils (Akoun et al,
1989, 1990; Guillon et al, 1992; Khan et al, 1997; Merad et al,
1997; Fujimori et al, 1998), which suggested cell-mediated hyper-
sensitivity immune reaction. These findings were similar to
organic antigen-induced hypersensitivity pneumonitis (Keller 
et al, 1984; Helmers and Pisani, 1994: 155–182). The pathogenesis
of the 2 reactions may be linked to some degree, but the latter is
believed to be caused by a compartmentalized cell-mediated
immune reaction with a relatively early onset after exposure. 
Pneumonitis is a rare complication of the taxanes; in the past
decade, there have been several case reports of paclitaxel-induced
hypersensitivity pneumonitis (Schweitzer et al, 1995; Furuse et al,
1997; Khan et al, 1997; Choy et al, 1998; Fujimori et al, 1998).
Pulmonary toxicity induced by docetaxel is more rare, with only 6
brief case reports reviewed in the literature (Kunitah et al, 1996;
Merad et al, 1997; Etienne et al, 1998). The toxicity in these cases
usually occurred after the 2nd to 4th course of chemotherapy, with
or without premedications, and was relieved promptly with corti-
costeroid therapy, except for one patient who died of acute respira-
tory failure. One of these 6 patients had received a BAL study,
which showed lymphocytic alveolitis (69%), a mild lymphocyte
subpopulation ratio reverse (CD4/CD8 = 1), and increased
neutrophils (18%) and eosinophils (12%) (Merad et al, 1997). One
interesting point mentioned by Merad et al was that there is
perhaps a positive relationship between the tumour response and
pulmonary injury (Merad et al, 1997); in the 2 cases with
docetaxel-induced pulmonary injury that they reported, both had at
least a partial tumour response and one was alive, and free of
disease, for 44 months after chest radiotherapy. This may suggest
that docetaxel can induce the proliferation of cytotoxic T-cells
against a specific pulmonary antigen expressed by the tumour
(Merad et al, 1997). 
A summary of our 4 patients’ characteristics can be found in
Table 1. The pulmonary injury presented with diffuse interstitial
infiltrates, rapid progression, and poor responsiveness to broad-
spectrum antibiotics therapy; metastatic tumour or infectious aeti-
ology was not likely according to these presentations. After
excluding other resultant factors, including other possible drug-
induced hypersensitivity, connective lung disease, or an unusual
infection such as CMV, HIV or legionella, docetaxel-induced
hypersensitivity pneumonitis was diagnosed. 
Case 3 had received curative radiotherapy of 5993 cGY over the
anterior chest and mediastinum 6 months before the onset of respi-
ratory failure. Radiation recall pneumonitis was not likely because
of the long interval between radiotherapy and onset of respiratory
failure (Schweitzer et al, 1995; Choy et al, 1998); more likely, the
docetaxel-induced pulmonary injury was aggravated by previous
radiation pneumonitis. The serial chest CT scans of case 3 are
shown in Figure 1. 
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Table 1 Summary of patients’ characteristics 
Case 1 Case 2 Case 3 Case 4 
Age (years old) 44 73 70 70 
Sex F M M M 
Underlying lung disease Stage IV  Stage IV NSCLC Stage IIIA squamous cell  Stage IIIB 
adenocarcinoma lung cancer; radiation pneumonitis adenocarcinoma 
Prior therapy PVP × 6 cycles NC × 6, TIEP × 3 cycles GN × 6 cycles; chest  Pneumonectomy; 
radiotherapy GC × 6 cycles 
Cumulative dosage of docetaxel 44 mg 644.4 mg  612 mg 166.4 mg 
TBLB NA Chronic inflammation and  Chronic inflammation NA 
interstitial fibrosis
PVP: etoposide (VP-16), cisplatin; NC: vinorelbine (navelbine), cisplatin; GN: gemcitabine, vinorelbine (navelbine); GC: gemcitabine, cisplatin. 
NA: not available. TBLB: transbronchial lung biopsy. Lung oxygenation improved temporarily with corticosteroid
therapy in cases 1 and 4, but it deteriorated again when we tried
tapering off the corticosteroid. That the more severe pulmonary
injury required prolonged corticosteroid therapy in our patients
might be due to the high cumulative dosage of docetaxel (more
than 600 mg in cases 2 and 3) and the more complicated under-
lying lung conditions (previous radiation pneumonitis in case 3,
earlier pneumonectomy in case 4). In addition, all 4 patients had
previously been treated with other chemotherapy agents (see Table
1), in comparison with the previously untreated patients reported
in the literature. 
The mechanism of drug-induced hypersensitivity pneumonitis
is not well understood. Most researchers agree that it is the conse-
quence of a cell-mediated immunologic reaction with pulmonary
sequestration of activated specific lymphocytes. Drug-induced
hypersensitivity pneumonitis is best diagnosed by a provocation
test coupled with BAL (Akoun et al, 1989, 1990; Guillon et al,
1992). However, these were not performed in our 4 patients
because of the life-threatening pneumonitis and respiratory failure. 
The treatment of choice for drug-induced hypersensitivity pneu-
monitis is the withdrawal of the offending drug and administration
of corticosteroid therapy, usually 30 to 60 mg of prednisolone per
day for 2 to 3 weeks (Merad et al, 1997), or higher (60 to 240 mg
per day) in more severe conditions such as acute respiratory failure
(Jantz and Sahn, 1999), with a slow and careful tapering-off period. 
In conclusion, we report 4 cases of advanced lung cancer devel-
oping life-threatening pulmonary injury, and requiring mechanical
ventilation, after the 1st to 6th course of docetaxel infusion.
Although there was no evidence from the BAL, or the provocation
or lymphocyte migration tests, docetaxel-induced hypersensitivity
pneumonitis was diagnosed by excluding the other possible aeti-
ologies and considering the clinical course. Physicians should be
alert to this unusual, and perhaps life-threatening, adverse effect of
docetaxel, in order to begin counteracting treatment as soon as
possible. 
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